BE639532A - - Google Patents
Info
- Publication number
- BE639532A BE639532A BE639532DA BE639532A BE 639532 A BE639532 A BE 639532A BE 639532D A BE639532D A BE 639532DA BE 639532 A BE639532 A BE 639532A
- Authority
- BE
- Belgium
- Prior art keywords
- oil
- association
- formula
- water
- desc
- Prior art date
Links
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 235000000112 undernutrition Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 235000013345 egg yolk Nutrition 0.000 claims 1
- 210000002969 egg yolk Anatomy 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 101150028481 rol-3 gene Proteins 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 description 15
- 229960004203 carnitine Drugs 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 241000144080 Alestes Species 0.000 description 1
- 102000004726 Connectin Human genes 0.000 description 1
- 108010002947 Connectin Proteins 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 241000120020 Tela Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE639532A true BE639532A (de) |
Family
ID=203903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE639532D BE639532A (de) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE639532A (de) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| DE2921312A1 (de) * | 1978-05-25 | 1979-12-06 | Claudio Cavazza | Pharmazeutisches mittel und dessen verwendung bei einer vollstaendig parenteralen ernaehrung |
| DE3037479A1 (de) * | 1979-10-05 | 1981-05-21 | Sigma Tau S.p.A. Industrie Farmaceutiche Riunite, Roma | Pharmazeutische zusammensetzung zur parenteralen ernaehrung aus l-carnitin oder acyl-l-carnitinen |
| DE3026368A1 (de) * | 1980-07-11 | 1982-02-18 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion |
| DE3339052A1 (de) * | 1982-10-29 | 1984-05-03 | Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma | Pharmazeutisches praeparat zur verbesserung der biochemischen und verhaltens-parameter bei senilitaet |
| EP0627161A1 (de) * | 1993-06-02 | 1994-12-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Verwendung von L-Carnitin und Alkanoyl L-Carnitine zum Bewahren von Transfusionsblut, und sie enthaltenden Stabilisierungslösungen |
-
0
- BE BE639532D patent/BE639532A/fr unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| DE2921312A1 (de) * | 1978-05-25 | 1979-12-06 | Claudio Cavazza | Pharmazeutisches mittel und dessen verwendung bei einer vollstaendig parenteralen ernaehrung |
| DE3037479A1 (de) * | 1979-10-05 | 1981-05-21 | Sigma Tau S.p.A. Industrie Farmaceutiche Riunite, Roma | Pharmazeutische zusammensetzung zur parenteralen ernaehrung aus l-carnitin oder acyl-l-carnitinen |
| DE3026368A1 (de) * | 1980-07-11 | 1982-02-18 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion |
| DE3339052A1 (de) * | 1982-10-29 | 1984-05-03 | Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma | Pharmazeutisches praeparat zur verbesserung der biochemischen und verhaltens-parameter bei senilitaet |
| EP0627161A1 (de) * | 1993-06-02 | 1994-12-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Verwendung von L-Carnitin und Alkanoyl L-Carnitine zum Bewahren von Transfusionsblut, und sie enthaltenden Stabilisierungslösungen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0593601B1 (de) | Taxan-derivate enthaltende arzneimittel | |
| US5714512A (en) | Compositions containing taxane derivatives | |
| EP0424282B1 (de) | Kosmetische Mittel zur Bräunung | |
| EP0514665A1 (de) | Öllösliche Antioxydationsmischung | |
| FR2934954A1 (fr) | Emulsion fluorescente de vert d'indocyanine | |
| FR2832065A1 (fr) | Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations | |
| EP0138931A1 (de) | Dermatologische zusammensetzung und verfahren zu ihrer herstellung. | |
| FR2604906A1 (fr) | Collyre | |
| BE639532A (de) | ||
| FR2560523A1 (fr) | Solution ophtalmique contenant du pranoprofene et de l'acide borique | |
| FR2609998A1 (fr) | Nouvelles substances antioxydantes derivees d'acides amines | |
| EP0302769B1 (de) | Für die parenterale oder enterale Ernährung bestimmte Lipidemulsion | |
| EP0233100A1 (de) | Pharmazeutische Zusammensetzung, enthaltend ein Lokal- und/oder Zentralanästhetikum, eingekapselt in multilamellare Liposome | |
| EP0913147B1 (de) | System bestehend aus Phosphonsäurederivate und Metabisulfit zur Stabilisierung von Ascorbinsäure | |
| MC1379A1 (fr) | Formule pharmaceutique isotonique stabilisee contenant un compose du mercure comme agent de conservation | |
| Kiese et al. | The treatment of experimental cyanide poisoning by hemiglobin formation | |
| EP1185255B1 (de) | RETINA PROTEKTIVE OPHTHALMOLOGISCHEN ARZNEIMITTELN enthaltend ramipril oder ramiprilat | |
| Cheikh et al. | Étude in vitro de l’effet antifalcémiant des globules rouges et de l’activité antioxydante d’extraits de la poudre de racines de Maytenus senegalensis Lam (Celestraceae) | |
| JP2006008720A (ja) | 腎臓機能改善剤 | |
| EP0920320A2 (de) | Injuzierbare pharmazeutische zusammensetzung enthaltend ursodesoxycholsäure odertaurorsodeoxylcholsäure, eine starke base und tromathamol | |
| EP0520865B1 (de) | Verwendung von Säurederivaten zur Herstellung eines Medikamentes gegen Läuse | |
| CA2493074A1 (fr) | Elevation du taux d'heme oxygenase avec des derives de la rheine | |
| EP0186542A1 (de) | Solubilisierungsverfahren im Moment der Anwendung eines aktiven lipophilen Prinzipes in wässriger Lösung zum Zweck der intravenösen Verabreichung | |
| BE897535A (fr) | Medicament a action cytostatique | |
| EP1046398B1 (de) | Zubereitung eines Arzneimittels enthaltend Catechich- oder Flavonylisch-ähnliche Polyphenolverbindungen aus Pflanzen, insbesondere für die Behandlung von Gingivitis |